Intellectual Property: HHS Reference No. E-553-2013/0--U.S. Provisional Patent Application 61/863,071 filed
* HHS Reference No. E-115-2013/0--U.S. Provisional Patent Application No. 61/834,357 filed
* HHS Reference No. E-027-2013/0--U.S. Provisional Patent Application No. 61/785,652 filed
Collaborative Research Opportunity: The National Heart Lung & Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Transcatheter Cardiovascular Interventions. For collaboration opportunities, please contact Ms.
Photoactivatable Nanoparticles for Targeted Drug Delivery
Description of Technology: The invention relates to novel lipid-based nanoparticles (liposomes) for use in targeted drug delivery. The particles include a wall surrounding a cavity, wherein the wall includes (i) a lipid bilayer comprising 1,2-bis(tricosa-10,12-diynoyl)-sn-glycero-3-phosphocholine (DC8,9PC), and dipalmitoylphosphatidylcholine (DPPC), and (ii) a tetrapyrollic photosensitizer, such as 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) within the lipid bilayer. The lipid bilayer may include one or more segregated regions, or pockets, of DC8,9PC with the HPPH being preferentially located within the DC8,9PC pockets. The nanoparticles include at least one therapeutic agent within the cavity. Upon a targeted application of light in the near-infrared range, the particles are disrupted and can release the therapeutic agent at a targeted site. The concurrent release of the photosensitizing agent HPPH may be advantageous in the treatment of certain cancers, since this agent has shown to possess therapeutic ability on its own right.
Potential Commercial Applications: The nanoparticles can be used for targeted drug delivery.
* The particles are stable and can be activated upon demand to release the therapeutic agent at the desired site.
* The concurrent release of the photosensitizing agent HPPH may be advantageous in the treatment of certain types of cancer, since this agent has shown to possess therapeutic ability on its own right.
Development Stage: In vivo data available (animal).
1. Yavlovich A, et al. Design of liposomes containing photopolymerizable phospholipids for triggered release of contents. J Therm Anal Calorim. 2009 Oct1;98(1):97-104. [PMID 20160877]
2. Yavlovich A, et al. A novel class of photo-triggerable liposomes containing DPPC:DC(8,9)PC as vehicles for delivery of doxorubicin to cells. Biochim Biophys Acta. 2011 Jan;1808(1):117-26. [PMID 20691151]
3. Puri A, Blumenthal R. Polymeric lipid assemblies as novel theranostic tools.
4. Puri A, et al. Material properties of matrix lipids determine the conformation and intermolecular reactivity of diacetylenic phosphatidylcholine in the lipid bilayer. Langmuir. 2011 Dec 20;27(24):15120-8. [PMID 22053903]
Most Popular Stories
- AIG to Create 230 Jobs in Charlotte
- 15 Myths That Could Ruin Your Hispanic Ad Campaign
- Russia Says Nyet to Canada North Pole Claim
- Bipartisan Negotiators Reach Modest Budget Agreement
- Justin Bieber Visits Typhoon Victims, Plays Concert
- Senate Dems Move Forward With Obama Nominees
- New Obama Aide to Focus on Climate Change
- Obama Nominee Confirmed for D.C. Appeals Court
- MasterCard to Split Shares, Raise Dividend
- GOP, Dems Strain to Unearth a Modest Budget Pact